Literature DB >> 30337442

Genetic risk factors for modulation of age at onset in Machado-Joseph disease/spinocerebellar ataxia type 3: a systematic review and meta-analysis.

Eduardo Preusser de Mattos1,2,3, Maiara Kolbe Musskopf2, Vanessa Bielefeldt Leotti4,5, Maria Luiza Saraiva-Pereira1,2,6,7, Laura Bannach Jardim8,2,7,9.   

Abstract

OBJECTIVES: To perform a systematic review and meta-analysis of genetic risk factors for age at onset (AO) in spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD).
METHODS: Two authors independently reviewed reports on the mathematical relationship between CAG length at the expanded ATXN3 allele (CAGexp), and other genetic variants if available, and AO. Publications from January 1994 to September 2017 in English, Portuguese or Spanish and indexed in MEDLINE (PubMed), LILACS or EMBASE were considered. Inclusion criteria were reports with >20 SCA3/MJD carriers with molecular diagnosis performed by capillary electrophoresis. Non-overlapping cohorts were determined on contact with corresponding authors. A detailed analysis protocol was registered at the PROSPERO database prior to data extraction (CRD42017073071).
RESULTS: Eleven studies were eligible for meta-analysis, comprising 10 individual-participant (n=2099 subjects) and two aggregated data cohorts. On average, CAGexp explained 55.2% (95% CI 50.8 to 59.0; p<0.001) of AO variability. Population-specific factors accounted for 8.3% of AO variance. Cohorts clustered into distinct geographic groups, evidencing significantly earlier AO in non-Portuguese Europeans than in Portuguese/South Brazilians with similar CAGexp lengths. Presence of intermediate ATXN2 alleles (27-33 CAG repeats) significantly correlated with earlier AO. Familial factors accounted for ~10% of AO variability. CAGexp, origin, family effects and CAG length at ATXN2 together explained 73.5% of AO variance.
CONCLUSIONS: Current evidence supports genetic modulation of AO in SCA3/MJD by CAGexp, ATXN2 and family-specific and population-specific factors. Future studies should take these into account in the search for new genetic modifiers of AO, which could be of therapeutic relevance. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Mesh:

Year:  2018        PMID: 30337442     DOI: 10.1136/jnnp-2018-319200

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  9 in total

1.  Genetic Variation in ATXN3 (Ataxin-3) 3'UTR: Insights into the Downstream Regulatory Elements of the Causative Gene of Machado-Joseph Disease/Spinocerebellar Ataxia Type 3.

Authors:  Ana Rosa Vieira Melo; Mafalda Raposo; Marta Ventura; Sandra Martins; Sara Pavão; Isabel Alonso; Conceição Bettencourt; Manuela Lima
Journal:  Cerebellum       Date:  2022-01-16       Impact factor: 3.847

2.  The S-Factor, a New Measure of Disease Severity in Spinocerebellar Ataxia: Findings and Implications.

Authors:  Louisa P Selvadurai; Susan L Perlman; George R Wilmot; Sub H Subramony; Christopher M Gomez; Tetsuo Ashizawa; Henry L Paulson; Chiadi U Onyike; Liana S Rosenthal; Haris I Sair; Sheng-Han Kuo; Eva-Maria Ratai; Theresa A Zesiewicz; Khalaf O Bushara; Gülin Öz; Cameron Dietiker; Michael D Geschwind; Alexandra B Nelson; Puneet Opal; Talene A Yacoubian; Peggy C Nopoulos; Vikram G Shakkottai; Karla P Figueroa; Stefan M Pulst; Peter E Morrison; Jeremy D Schmahmann
Journal:  Cerebellum       Date:  2022-08-12       Impact factor: 3.648

3.  Are ATXN2 variants modifying our understanding about neural pathogenesis, phenotypes, and diagnostic?

Authors:  Jose Miguel Laffita-Mesa; Martin Paucar; Per Svenningsson
Journal:  Neural Regen Res       Date:  2022-11       Impact factor: 6.058

4.  The progression rate of spinocerebellar ataxia type 3 varies with disease stage.

Authors:  Linliu Peng; Yun Peng; Zhao Chen; Chunrong Wang; Zhe Long; Huirong Peng; Yuting Shi; Lu Shen; Kun Xia; Vanessa B Leotti; Laura Bannach Jardim; Beisha Tang; Rong Qiu; Hong Jiang
Journal:  J Transl Med       Date:  2022-05-14       Impact factor: 8.440

5.  The repeat variant in MSH3 is not a genetic modifier for spinocerebellar ataxia type 3 and Friedreich's ataxia.

Authors:  Wai Yan Yau; Mafalda Raposo; Conceição Bettencourt; Robyn Labrum; João Vasconcelos; Michael H Parkinson; Paola Giunti; Nicholas W Wood; Manuela Lima; Henry Houlden
Journal:  Brain       Date:  2020-04-01       Impact factor: 13.501

6.  Variation in DNA Repair System Gene as an Additional Modifier of Age at Onset in Spinocerebellar Ataxia Type 3/Machado-Joseph Disease.

Authors:  Rafaella Mergener; Gabriel Vasata Furtado; Eduardo Preusser de Mattos; Vanessa Bielefeldt Leotti; Laura Bannach Jardim; Maria Luiza Saraiva-Pereira
Journal:  Neuromolecular Med       Date:  2019-10-05       Impact factor: 3.843

Review 7.  Founder Effects of Spinocerebellar Ataxias in the American Continents and the Caribbean.

Authors:  Roberto Rodríguez-Labrada; Ana Carolina Martins; Jonathan J Magaña; Yaimeé Vazquez-Mojena; Jacqueline Medrano-Montero; Juan Fernandez-Ruíz; Bulmaro Cisneros; Helio Teive; Karen N McFarland; Maria Luiza Saraiva-Pereira; César M Cerecedo-Zapata; Christopher M Gomez; Tetsuo Ashizawa; Luis Velázquez-Pérez; Laura Bannach Jardim
Journal:  Cerebellum       Date:  2020-06       Impact factor: 3.847

8.  Childhood-Onset Spinocerebellar Ataxia 3: Tongue Dystonia as an Early Manifestation.

Authors:  Nester Mitchell; Gaynel A LaTouche; Beverly Nelson; Karla P Figueroa; Ruth H Walker; Andrew K Sobering
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2019-09-13

9.  Genome-wide association study identifies genetic factors that modify age at onset in Machado-Joseph disease.

Authors:  Fulya Akçimen; Sandra Martins; Calwing Liao; Cynthia V Bourassa; Hélène Catoire; Garth A Nicholson; Olaf Riess; Mafalda Raposo; Marcondes C França; João Vasconcelos; Manuela Lima; Iscia Lopes-Cendes; Maria Luiza Saraiva-Pereira; Laura B Jardim; Jorge Sequeiros; Patrick A Dion; Guy A Rouleau
Journal:  Aging (Albany NY)       Date:  2020-03-23       Impact factor: 5.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.